

DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. 2021 [dikutip 15 April 2024]. Tersedia pada: [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
2. Jayaraj JC, Davatyan K, Subramanian SS, Priya J. Epidemiology of Myocardial Infarction. In: Pamukçu B, editor. Rijeka: IntechOpen; 2018. hal. Ch. 2.
3. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol*. 2017;70(1):1–25.
4. Yeh RW, Sidney S, Chandra M, Sorel M, Selby J V, Go AS. Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction. *N Engl J Med*. 2010;362(23):2155–65.
5. Camacho X, Nedkoff L, Wright FL, Nghiem N, Buajitti E, Goldacre R, et al. Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1·95 million events in 80·4 million people in four countries. *Lancet Public Heal*. 2022;7(3):e229–39.
6. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann Transl Med*. 2016;4(13):256.
7. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. *Lancet*. 2017;389(10065):197–210.
8. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. *BMC Cardiovasc Disord*. 2017;17(1):53.
9. Vogel B, Claessen BE, Arnold S V, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. *Nat Rev Dis Prim*. 2019;5(1):39.
10. Del Buono MG, Garmendia CM, Seropian IM, Gonzalez G, Berrocal DH, Biondi-Zoccai G, et al. Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. *Curr Probl Cardiol*. 2023;48(8):101215.
11. Yoshioka G, Tanaka A, Watanabe N, Nishihira K, Natsuaki M, Kawaguchi A, et al. Prognostic impact of incident left ventricular systolic dysfunction after myocardial infarction. *Front Cardiovasc Med*. 2022;9.
12. Chen ZW, Yu ZQ, Yang HB, Chen YH, Qian JY, Shu XH, et al. Rapid predictors for the occurrence of reduced left ventricular ejection fraction

- between LAD and non-LAD related ST-elevation myocardial infarction. *BMC Cardiovasc Disord.* 2016;16:3.
13. Elendu C, Amaechi DC, Elendu TC, Omeludike EK, Alakwe-Ojimba CE, Obidigbo B, et al. Comprehensive review of ST-segment elevation myocardial infarction: Understanding pathophysiology, diagnostic strategies, and current treatment approaches. *Medicine (Baltimore).* 2023;102(43).
 14. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: Implications for risk assessment. *J Am Coll Cardiol.* 2004;44(10):1945–56.
 15. Chia S, Nagurney JT, Brown DFM, Raffel OC, Bamberg F, Senatore F, et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Cardiol.* 2009;103(3):333–7.
 16. Liu N, Wang Z, Zhang M. Biological tag effect of white blood cell count on left ventricular remodeling in patient after emergency percutaneous coronary intervention. *Chinese J Postgraduates Med.* 2012;35(28):11–4.
 17. Eskandarian R, Ghorbani R, Asgary Z. Relationship between leucocytosis and left ventricular ejection fraction in patients with acute myocardial infarction. *Singapore Med J.* 2013;54(1):40–3.
 18. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation.* 2018;138(20):e618–51.
 19. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *Circulation.* 2013;127(4):e362–425.
 20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Socie. *Eur Heart J.* 2018;39(2):119–77.
 21. Choudhury T, West NE, El-Omar M. ST elevation myocardial infarction. *Clin Med.* 2016;16(3):277–82.
 22. Montecucco F, Carbone F, Schindler TH. Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. *Eur Heart J.* 2016;37(16):1268–83.
 23. Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Elevation Myocardial Infarction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

24. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. *Eur Heart J*. 2017;38(11):774–84.
25. Boehringer Ingelheim. Risk factors of STEMI [Internet]. Boehringer Ingelheim Portal for HealthCare Professionals. 2022 [dikutip 26 Mei 2024]. Tersedia pada: <https://pro.boehringer-ingelheim.com/stemi-care/stemi/risk-factors>
26. Rathore V, Singh N, Mahat RK. Risk Factors of Acute Myocardial Infarction: A Review. *Eurasian J Med Investig*. 2018;2(1):1–7.
27. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). *Eur Heart J*. 2023;44(38):3720–826.
28. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144(22):e368–454.
29. Bonaca MP, Sabatine MS. Approach to the Patient with Chest Pain. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 12 ed. Elsevier; 2022.
30. Juzar DA, Danny SS, Irmalita, Tobing DPL, Firdaus I, Widyanoro B, et al. Pedoman Tata Laksana Sindrom Koroner Akut. 4 ed. Jakarta: Perhimpunan Dokter Spesial Kardiovaskular Indonesia; 2018.
31. Partow-Navid R, Prasitlunkum N, Mukherjee A, Varadarajan P, Pai RG. Management of ST Elevation Myocardial Infarction (STEMI) in Different Settings. *Int J Angiol*. 2021;30(1):67–75.
32. Berman MN, Tupper C, A B. Physiology, Left Ventricular Function. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
33. Vancheri F, Longo G, Henein MY. Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations. *Front Cardiovasc Med*. 2024;11.
34. Kusunose K, Zheng R, Yamada H, Sata M. How to standardize the measurement of left ventricular ejection fraction. *J Med Ultrason*. 2022;49(1):35–43.
35. Scatteia A, Silverio A, Padalino R, De Stefano F, America R, Cappelletti AM, et al. Non-invasive assessment of left ventricle ejection fraction: Where do we stand? *J Pers Med*. 2021;11(11):1153.

36. Kosaraju A, Goyal A, Grigorova Y, Makaryus AN. Left Ventricular Ejection Fraction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
37. Hudson S, Pettit S. What is ‘normal’ left ventricular ejection fraction? *Heart*. 2020;106(18):1445–6.
38. Kiron V, George P V. Correlation of cumulative ST elevation with left ventricular ejection fraction and 30-day outcome in patients with ST elevation myocardial infarction. *J Postgrad Med*. 2019;65(3).
39. Lei Z, Li B, Li B, Peng W. Predictors and prognostic impact of left ventricular ejection fraction trajectories in patients with ST-segment elevation myocardial infarction. *Aging Clin Exp Res*. 2022;34(6):1429–38.
40. Dauw J, Martens P, Deferm S, Bertrand P, Nijst P, Hermans L, et al. Left ventricular function recovery after ST-elevation myocardial infarction: correlates and outcomes. *Clin Res Cardiol*. 2021;110(9):1504–15.
41. Kawthalkar SM. *Essentials of Clinical Pathology*. 2 ed. New Delhi: Jaypee Brothers Medical Publisher; 2018.
42. Blann A. *Routine Blood Results Explained*. 4 ed. UK: Cambridge Scholars Publishing; 2022.
43. Blann A, Ahmed N. *Blood Science: Principles and Pathology*. 2 ed. New Jersey: John Wiley & Sons, Ltd; 2023.
44. Krizkova V, Sigutova P, Holubova M, Stambachova A, Dolejsova M, Lysak D, et al. *Blood and Blood Components: Hematopoiesis, Selected Methods Used in Cytology, Histology, and Hematology*. 1 ed. Prague: Charles University Karolinum Press; 2021.
45. Mank V, Azhar W, Brown K. Leukocytosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
46. Provan D. *Oxford Handbook of Clinical and Laboratory Investigation*. 4 ed. Oxford, UK: Oxford University Press; 2018.
47. American Board of Internal Medicine. *ABIM Laboratory Test Reference Ranges*. Philadelphia; 2024.
48. Filep JG. Leukocytes in inflammation, resolution of inflammation, autoimmune diseases and cancer. *Cells*. 2021;10(7):1735.
49. Yan XN, Jin JL, Zhang M, Hong LF, Guo YL, Wu NQ, et al. Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study. *BMC Cardiovasc Disord*. 2020;20(1):465.
50. Zimmer A, Bagchi AK, Vinayak K, Bello-Klein A, Singal PK. Innate immune response in the pathogenesis of heart failure in survivors of

- myocardial infarction. *Am J Physiol Circ Physiol*. 2018;316(3):H435–45.
51. Peterson EA, Sun J, Wang J. Leukocyte-Mediated Cardiac Repair after Myocardial Infarction in Non-Regenerative vs. Regenerative Systems. *J Cardiovasc Dev Dis*. 2022;9(2):63.
 52. Świątkiewicz I, Magielski P, Kubica J, Zadourian A, DeMaria AN, Taub PR. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. *Int J Mol Sci*. 2020;21(3).
 53. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. *J Am Coll Cardiol*. 3 Mei 2016;67(17):2050–60.
 54. Panda AL, Soesanto AM, Ketaren AP, Kuncoro AS, Martanto E, Mumpuni H, et al. Panduan Pemeriksaan Ekokardiografi di Klinik. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2021.
 55. Lukito AA, Harmeiwaty E, Situmorang TD, Hustirini NM, Kuncoro AS, Barack R, et al. Konsensus Penatalaksanaan Hipertensi 2021: Update Konsensus PERHI 2019. Jakarta: Perhimpunan Dokter Hipertensi Indonesia; 2021.
 56. Soelistijo SA, Suastika D, Lindarto D, Decroli E, Permana H, Sucipto KW, et al. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. Jakarta: PB PERKENI; 2021.
 57. Aman AM, Soelistijo SA, Arsana PM, Wismandari, Zufry H, Rosandi R, et al. Panduan Pengelolaan Dislipidemia di Indonesia. Jakarta: PB PERKENI; 2021.
 58. Tern PJW, Ho AKH, Sultana R, Ahn Y, Almahmeed W, Brieger D, et al. Comparative overview of ST-elevation myocardial infarction epidemiology, demographics, management, and outcomes in five Asia-Pacific countries: a meta-analysis. *Eur Hear J - Qual Care Clin Outcomes*. 2021;7(1):6–17.
 59. Bortnick AE, Shahid M, Shitole SG, Park M, Broder A, Rodriguez CJ, et al. Outcomes of ST-elevation myocardial infarction by age and sex in a low-income urban community: The Montefiore STEMI Registry. *Clin Cardiol*. 2020;43(10):1100–9.
 60. Dharmawan M, Hidayat LW, Tiluata LJ. Profil Infark Miokard Akut dengan Kenaikan Segmen-ST Di ICCU RSUD Prof W . Z . Johannes Kupang, Nusa Tenggara Timur, Januari-April 2018. *J Cermin Dunia Kedokt*. 2019;46(12):727–30.
 61. Prasetya AE. Simplified Selvester QRS Score as an Infarct Size Parameter in STEMI Patients Undergoing Pharmacoinvasive or Primary Percutaneous Coronary Intervention. *Indones J Cardiol*. 2022;43(4):150–8.

62. Putranto AY, Haykal Putra TM, Soedarsono WA. Modified STEMI protocol for Primary PCI during COVID-19 Pandemic: Does it prolong Door-To-Balloon performance? *Eur Heart J*. 2023;44(Supplement_1):103–10.
63. Wang C, Zhou L, Liang Y, Liu P, Yuan W. Interactions of ST-elevation myocardial infarction, age, and sex and the risk of major adverse cardiovascular events among Chinese adults: a secondary analysis of a single-centre prospective cohort. *BMJ Open*. 2022;12(7):e058494.
64. Tumminello G, D’Errico A, Maruccio A, Gentile D, Barbieri L, Carugo S. Age-Related Mortality in STEMI Patients: Insight from One Year of HUB Centre Experience during the Pandemic. *J Cardiovasc Dev Dis*. 2022;9(12).
65. Cenko E, Yoon J, Kedev S, Stankovic G, Vasiljevic Z, Krljanac G, et al. Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age. *JAMA Intern Med*. 2018;178(5):632–9.
66. Gayatri NI, Firmansyah S, S SH, Rudiktyo E. Prediktor Mortalitas Dalam-Rumah-Sakit Pasien Infark Miokard ST Elevation (STEMI) Akut di RSUD dr. Dradjat Prawiranegara Serang, Indonesia. *Cermin Dunia Kedokt*. 2016;43(3):171–4.
67. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. *Eur Heart J*. 2008;29(7):932–40.
68. Sörensen NA, Neumann JT, Ojeda F, Schäfer S, Magnussen C, Keller T, et al. Relations of Sex to Diagnosis and Outcomes in Acute Coronary Syndrome. *J Am Heart Assoc*. 2018;7(6).
69. Nyström A, Strömberg S, Jansson K, Faresjö ÅO, Faresjö T. Cardiovascular risks before myocardial infarction differences between men and women. *BMC Cardiovasc Disord*. 2022;22(1):110.
70. Dahdah A, Jaggars RM, Sreejit G, Johnson J, Kanuri B, Murphy AJ, et al. Immunological Insights into Cigarette Smoking-Induced Cardiovascular Disease Risk. *Cells*. 2022;11(20).
71. Elkhader BA, Abdulla AA, Ali Omer MA. Correlation of Smoking and Myocardial Infarction Among Sudanese Male Patients Above 40 Years of Age. *Polish J Radiol*. 2016;81:138–40.
72. Fu M, Mei A, Min X, Yang H, Wu W, Zhong J, et al. Advancements in Cardiovascular Disease Research Affected by Smoking. *RCM*. 2024;25(8):298-null.
73. Karim H, Ali R, Hamza A, Muhammad M, Muhammad Attique Zahid H, Awais Bin Abdul Malik M. Impact of Age on Presentation, Risk Factors, and Cardiac Imaging Findings in St-Elevation Myocardial Infarction (Stemi). *J Popul Ther Clin Pharmacol*. 2024;31(4):505–12.

74. García-García C, Oliveras T, Serra J, Vila J, Rueda F, Cediél G, et al. Trends in Short- and Long-Term ST-Segment–Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-Segment–Elevation Myocardial Infarction Registry. *J Am Heart Assoc.* 2020;9(20):e017159.
75. Konstantinou K, Tsioufis C, Koumelli A, Mantzouranis M, Kasiakogias A, Doumas M, et al. Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. *J Clin Hypertens (Greenwich).* 2019;21(8):1135–43.
76. Mawardy A, Pangemanan JA, Djafar DU. Gambaran Derajat Hipertensi Pada Pasien Sindrom Koroner Akut (SKA) di RSUP PROF. R. D. Kandou Manado Periode Januari - Desember 2014. *e-CliniC.* 2016;4(1).
77. Pricillia A, Suprapti S, Pasaribu RP. Hubungan antara Hipertensi dengan Angka Kejadian Infark Miokard Akut pada Pasien Usia Lanjut di RSUP dr. Mohammad Hoesin Palembang Periode 2018-2019. *Sriwij J Med.* 2021;4(3):181–5.
78. Al-Nozha MM, Ismail HM, Al Nozha OM. Coronary artery disease and diabetes mellitus. *J Taibah Univ Med Sci.* 2016;11(4):330–8.
79. Babes EE, Bustea C, Behl T, Abdel-Daim MM, Nechifor AC, Stoicescu M, et al. Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. *Biomed Pharmacother.* 2022;148:112772.
80. Jain V, Qamar A, Matsushita K, Vaduganathan M, Ashley KE, Khan MS, et al. Impact of Diabetes on Outcomes in Patients Hospitalized With Acute Myocardial Infarction: Insights From the Atherosclerosis Risk in Communities Study Community Surveillance. *J Am Heart Assoc.* 2023;12(10):e028923.
81. Wengrofsky P, Lee J, Makaryus AN. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. In: McFarlane SI, editor. *Rijeka: IntechOpen; 2019. hal. Ch. 2.*
82. Garg R, Aggarwal S, Kumar R, Sharma G. Association of atherosclerosis with dyslipidemia and co-morbid conditions: A descriptive study. *J Nat Sci Biol Med.* 2015;6(1):163–8.
83. Addisu B, Bekele S, Wube TB, Hirigo AT, Cheneke W. Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oromia region, west Ethiopia. *BMC Cardiovasc Disord.* 2023;23(1):321.
84. Sitepu AM, Djafar DU, Panda AL. Gambaran jumlah leukosit pada pasien infark miokard akut di RSUP Prof. Dr. R. D.Kandou Manado periode

Januari-Desember 2015. *e-CliniC*. 2016;4(2).

85. Kurniawan LB, Bahrin U, Arif M, ER D. Pengaruh Jumlah Leukosit terhadap Mortalitas Pasien Infark Miokard Akut selama Perawatan. *Cermin Dunia Kedokt*. 2020;42(10):727.
86. Zhu Z, Zhou S. Leukocyte count and the risk of adverse outcomes in patients with HFpEF. *BMC Cardiovasc Disord*. 2021;21(1):333.
87. Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, et al. Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. *Int J Cardiol*. 2018;272:260–6.
88. Hussain TM, Swaminathan N. Correlation of Early WBC Count with Ejection Fraction in STEMI Patients: A Prospective Study. *Int J Sci Res*. 2023;12(10):494–7.
89. Jan AF, Habib S, Naseeb K, Khatri MA, Zaman KS. High Total Leukocyte Count and Heart Failure After Myocardial Infarction. *Pakistan Hear J*. 2011;44(1):8–17.